Previous 10 | Next 10 |
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering PR Newswire JERUSALEM, Israel , Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimat...
Gainers: Catabasis Pharmaceuticals (CATB) +162%, Novavax (NVAX) +66%, Bellicum Pharmaceuticals (BLCM) +40%, 9 Meters Biopharma (NMTR) +32%, Regional Health Properties (RHE) +9%.Losers: iRhythm Technologies (IRTC) -36%, Lianluo Smart (LLIT) -19...
Marine Petroleum Trust (MARPS) -43%.Barnwell Industries (BRN) -39%.Tengasco (TGC) -32%.PEDEVCO (PED) -34%.New Concept Energy (GBR) -30% pared yesterday's gains following latest Reddit craze.Ucommune International (UK) -28% after pricing share and warrant offering.Hous...
BiondVax Pharmaceuticals (BVXV) traded 10.7% down in premarket after pricing an underwritten public offering of 2.43M ADSs, each representing 40 ordinary shares, at $4.95/ADS, for gross proceeds of ~$12.1M.Underwriters granted 30-day option to purchase up to an additional 15% o...
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares PR Newswire JERUSALEM , Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, ma...
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares PR Newswire JERUSALEM , Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company focused on developing, manufac...
Biondvax Pharmaceuticals (BVXV): Q3 GAAP EPS of -NIS 0.33.As of Sep. 30, 2020, BiondVax had cash and cash equivalents of NIS 24.8M vs. NIS 72.5M as of Dec. 31, 2019Press Release For further details see: Biondvax Pharmaceuticals reports Q3 results
BiondVax Announces Third Quarter 2020 Financial Results & Business Update BiondVax Announces Third Quarter 2020 Financial Results & Business Update PR Newswire JERUSALEM , Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV),...
Senseonics Holdings (SENS) -16% after raising size of stock offering.Global Ship Lease (GSL) -14% after announcing public offering.Globalstar (GSAT) -13% after Morgan Stanley cuts to underweight on valuation.Broadwind (BWEN) -13% after guiding Q4 revenu...
Gainers: Vinco Ventures (BBIG) +312%.ADiTx Therapeutics (ADTX) +90%.Qutoutiao (QTT) +65%.Ideal Power (IPWR) +51%.BiondVax Pharmaceuticals (BVXV) +39%.Celsion (CLSN) +34%.Polar Power (POLA) +33%.Addex Therapeutics (ADXN) +28%.Pioneer Power Solutions (PPSI) +27%.Barnwell Industri...
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...